VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines

Journal of Interferon and Cytokine Research

Volumn 28, Issue 9, 2008, Pages 553-561

  Raig, Ene T ^a   Jones, Natalie B ^a   Varker, Kimberly A ^a   Benniger, Kristen ^a   Go, Michael R ^a   Biber, Jennifer L ^a   Lesinski, Gregory B ^a   Carson III, William E ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; INTERLEUKIN 12; RECOMBINANT ALPHA2B INTERFERON; STAT1 PROTEIN; VASCULOTROPIN;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; MELANOMA; MELANOMA CELL; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN SECRETION; SINGLE DRUG DOSE;

CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-12; MELANOMA; RECOMBINANT PROTEINS; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 51349135746     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2008.0118     Document Type: Article

References (27)

1. Airoldi I, Di Carlo E, Cocco C, Taverniti G, D'Antuono T, Ognio E, Watanabe M, Ribatti D, Pistoia V. 2007. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci USA 104:3996-4001.
2. Bedogni B, O'Neill MS, Welford SM, Bouley DM, Giaccia AJ, Denko NC, Powell MB. 2004. Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 64:2552-2560.
3. Belardelli F, Ferrantini M, Proietti E, and Kirkwood JM. 2002. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:119-134.
4. Carroll VA and Ashcroft M. 2006. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66:6264-6270.
5. Choueiri TK, Bukowski RM, Rini BI. 2006. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Semin Oncol 33:596-606.
6. Claffey KP, Robinson GS. 1996. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 15:165-176.
7. Eisenbeis CF, Lesinski GB, Anghelina M, Parihar R, Valentino D, Liu J, Nadella P, Sundaram P, Young DC, Sznol M, Walker MJ, Carson WE. 2005. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol 23:8835-8844.
8. Fidler IJ. 2000. Angiogenesis and cancer metastasis. Cancer J Sci Am Suppl 2:134-141.
9. Folkman J. 1995. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763.
10. Gorski DH, Leal AD, Goydos JS. 2003. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. J Am Coll Surg 197:408-418.
11. Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S, Schmiegel W. 2001. Modulation of angiogenesis and tumor-genicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 61:7282-7290.
12. Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H. 2003. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 21:3770-3776.
13. Islam M, Frye RF, Richards TJ, Sbeitan I, Donnelly SS, Glue P, Agarwala SS, Kirkwood JM. 2002. Differential effect of IFNα-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 8:2480-2487.
14. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. 2004. Randomized Phase II trial comparing Bevacizumab plus Carboplatin and Paclitaxel with Carboplatin and Paclitaxel alone in previously untreated locally advanced or metastatic non-small cell cancer. J Clin Oncol 22:2184-2191.
15. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. 2003. Phase II, randomized trial comparing Bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65.
16. Lara PN Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR. 2003. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 9:4772-4781.
17. Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, Abood G, Chaudhury AR, Magro C, Durbin J, Carson WE. 2003. The antitumor effects of IFN-alpha are abrogated in a STAT-1 deficient mouse. J Clin Invest 112:170-180.
18. Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, Carson WE. 2004. Multiparametric flow cytometric analysis of inter-patient variation in STAT 1 phosphorylation following interferon alpha immunotherapy. J Natl Cancer Inst 96:1331-1342.
19. Lesinski GB, Trefry J, Brasdovich M, Kondadasula SV, Sackey K, Zimmerer JM, Chaudhury AR, Yu L, Zhang X, Crespin TR, Walker MJ, Carson WE. 2007. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin Cancer Res 13:5010-5019.
20. Pyrhonen S, Kouri M, Holsti LR, Cantell K. 1992. Disease stabilization by leukocyte alpha interferon and survival of patients with metastatic melanoma. Oncology 49:22-26.
21. Sgadari C, Angiolillo AL, Tosato G. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87:3877-3882.
22. Srivastava A, Ralhan R, Kaur J. 2003. Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. Microsc Res Tech 60:208-224.
23. Sun X, Kanwar JR, Leung E, Vale M, Krissansen GW. 2003. Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1-alpha. Gene Ther 10:2081-2089.
24. Trisciuoglio D, Iervolino A, Zupi G, Del Bufalo. 2005. Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell 16:4153-4162.
25. Tsavaris N, Baxevanis C, Kosmidis P, Papamichael M. 1996. The prognostic significance of immune changes in patients with renal cancer, melanoma, and colorectal cancer, treated with interferon alpha 2b. Cancer Immunol Immunother 43:94-102.
26. von Marschall A, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S. 2003. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95:421-437.
27. Wu WZ, Sun HC, Wu WZ, Sun HC, Shen YF, Chen J, Wang L, Tang ZY, Iliakis G, Liu KD. 2005. Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol 131:169-78.